Skip to main content

Table 3 Association between apolipoprotein C3 and glucose homeostasis molecules and indices in patients with RA

From: Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis

 

Apolipoprotein C-III, mg/dl

Pearson’s r

p

Beta coef. (95% CI)

Model 1

p

Model 2

p

Glucose, mg/dl

87 ± 10

 − 0.050

0.37

 − 0.22 (− 0.45–0.02)

0.076

0.16 (− 0.34–0.66)

0.52

Insulin, µU/ml

7.7 (5.2–12.2)

0.199

 < 0.001

0.16 (− 0.02–0.34)

0.086

0.37 (0.01–0.73)

0.044

C-peptide, ng/ml

2.4 (1.5–3.4)

0.234

 < 0.001

0.06 (0.01–0.10)

0.011

0.13 (0.05–0.22)

0.003

HOMA2-IR

1.00 (0.66–1.56)

0.199

 < 0.001

0.02 (0.00–0.04)

0.088

0.05 (0.00–0.09)

0.041

HOMA2-%S

101 (64–151)

 − 0.088

0.15

0.60 (− 1.03–2.22)

0.47

  

HOMA2-%B

101 (80–137)

0.199

 < 0.001

1.26 (− 0.04–2.55)

0.058

0.98 (− 0.40–2.36)

0.16

HOMA2-IR-C-peptide

1.66 (1.09–2.48)

0.232

 < 0.001

0.04 (0.01–0.07)

0.012

0.10 (0.04–0.17)

0.003

HOMA2-%S-C-peptide

60 (40–92)

 − 0.154

0.005

 − 0.26 (− 1.10–0.59)

0.55

  

HOMA2-%B-C-peptide

145 (115–192)

0.236

 < 0.001

2.23 (0.64–3.82)

0.006

2.94 (0.07–5.80)

0.045

  1. Data represent means ± SD or median (IQR) when data were not normally distributed
  2. In the multivariable analysis ApoC3 is considered the independent variable. Significant p values are depicted in bold
  3. HOMA2-IR, Homeostatic Assessment Model for the assessment of insulin resistance using insulin and glucose serum levels; HOMA2-%B-C peptide, Homeostatic Assessment Model for the assessment of beta-cell function using C-peptide and glucose serum levels; Model 1, Adjusted for abdominal circumference, smoking, obesity, and triglycerides; Model 2, Adjusted for model 1 + disease duration, DAS28-ESR, prednisone dose and conventional DMARD use
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us